Análisis descriptivo de una serie de 32 tumores del tracto urinario superior en un hospital de segundo nivel

  1. Jiménez-Pacheco, Antonio 1
  2. Jiménez-Pacheco, Araceli 2
  3. del Moral Domínguez, Eva María 2
  4. López-Luque, Alfonso 1
  5. Verdú-Martínez, Manuel 1
  1. 1 Hospital Santa Ana de Motril
    info

    Hospital Santa Ana de Motril

    Motril, España

  2. 2 H.U Virgen de las Nieves
Revista:
Actualidad médica

ISSN: 0365-7965

Año de publicación: 2014

Tomo: 99

Número: 793

Páginas: 140-145

Tipo: Artículo

DOI: 10.15568/AM.2014.793.OR05 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Actualidad médica

Objetivos de desarrollo sostenible

Resumen

Introduction: The aim of the study is to analyze, based on patients treated in our department of upper urinary tract tumors, epidemiological and clinical characteristics as well as the variables that have influenced the evolution and mortality of these patients Material and methods: 32 patients diagnosed of upper urinary tract tumors in Santa Ana Hospital of Motril (Granada) between January 2003 and December 2013 were retrospectively analyzed. Results: The mean age was 72.25 years. 75% were male and 25% female. 71.9% were hypertensive, 46.9% were smokers. 18.8% had a bladder tumor at diagnosis. 90.6% debuted with hematuria.53.1% was located on the right side and 43.8% on the left. 25% were developed in the chalices, 46.8% in the renal pelvis and ureteral 50%.The pathologic stage at diagnosis: 6.3% Ta, 25% T1, 28.1% T2, 37.5% T3 and 3.1% T4. 21.9% were grade I, grade II 34.4% and 43.8% grade III. No tumor recurrence was observed in any patient being cancer -specific mortality of 0%. In 8 patients bladder tumor was diagnosed during follow-up. The mean hospital stay was 7 days. Conclusions: Despite being limited casuistry the results are satisfactory regardless of the surgical technique used, being disease-free survival in the follow-up period of 100% and cancer-specific mortality of 0%.

Referencias bibliográficas

  • Cowan NC. CT urography for hematuria. Nature 2012; 9: 218- 26.
  • Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: A systematic review of the literature. Eur Urol 2014; 65: 742-54.
  • Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012; 110:614-28.
  • Fanigan R. Tumores uroteliales de las vías urinarias. En Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. CampbellWalsh Urology. 9th ed. Buenos Aires: Editorial Médica Panamericana; 2008. p: 1638-52.
  • Giannarini G, Schumacher MC, Thalmann GN, Bitton A, Fleischmann A, Studer UE. Elective management of transitional cell carcinoma of the distal ureter: can kidneysparing surgery be advised? BJU Int 2007; 100(2): 264-8.
  • Goel MC, Matin SF, Derweesh I, Levin H, Streem S, Novick AC. Partial nephrectomy for renal urothelial tumors: clinical update. Urology 2006; 67:490-5.
  • Iborra I, Solsona E, Casanova J, Ricos JV, Rubio J, Climent MA. Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol 2003; 169: 82-5.
  • Izquierdo Reyes L. Tumores del tracto urinario superior. Clin Urolog 2012; 4: 7-16.
  • Jovanovic M, Soldatovic I, Janjic A, et al. Diagnostic value of the nuclear matrix protein 22 test and urine cytology in upper tract urothelial tumors. Urol Int 2011; 87: 134-7.
  • Katz MH, Lee MW, Gupta M. Setting a new standards for topical therapy of upper tract transitional cell carcinoma: BCG and interferon-alpha2b. J Endourol 2007; 21:374-7; discussion 377.
  • Leow JJ, Martin-Doyle W, Fay AP, Choueri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014; 66:529-41.
  • Liatsikos EN, Dinlenc CZ, Kapoor R, Smith AD. Transitional-cell carcinoma of the renal pelvis: ureteroscopic and percutaneous approach. J Endourol 2001; 15:377-83.
  • Martín Martín S, Calleja Escudero J, Trueba Arguiñarena FJ, Rivero Martínez MD, Sanz Ruiz A, Fernández del Busto E. Tumores del tracto urinario superior. Nuestra experiencia. Arch Esp Urol 2008; 61: 499-506.
  • Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; 116: 3127-34.
  • Messer J, Shariat SF, Brien JC, et al. Urinary cytology has a por performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011; 108(5): 701-5.
  • Mian C, Mazzoleni G, Vikoler S, et al. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol 2010; 58: 288-92.
  • Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology 2009; 73: 27-31.
  • Ristau BT, Tomaszewski JJ, Ost MC. Upper tract urothelial carcinoma: Current treatment and outcomes. Urology 2012; 79: 749-56.
  • Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013; 63:1059-71.
  • Rouprêt M, Harmon JD, Sanderson KM, et al. Laparoscopic distal ureterectomy and anastomosis for management of low-risk upper urinary tract transitional cell carcinoma: preliminary results. Br J Urol 2007; 99:623-27.
  • Rouprêt M, Traxer O, Tligui M, et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol 2007; 51:709-14.
  • Rouprêta M, Zigeunerb R, Palou A, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinoma 2011 update. Eur Urol 2011; 59: 584-94.
  • Suriano F, Brancato T. Nephron-sparing management of upper tract urothelial carcinoma. Rev Urol 2014; 16:21-28.
  • Sverrisson EF, Kim T, Espiritu PN, et al. The merits of cytology in the work up for upper tract urothelial carcinoma a contemporary review of a perplexing issue. Int Braz J Urol 2014; 40: 493-8.
  • Takahashi N, Glockner JF, Hartman RP, et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignacy. J Urol 2010; 183: 1330-65.
  • Thalmann GN, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002; 168:1381-5.
  • Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer 2012; 48:456- 64.
  • Waldert M, Karakiewicz PI, Raman JD, et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010; 105: 812-7.
  • Wan LJ, Wong YC, Huang CC, Wu CH, Hung SC, Chen HW. Multidetector computerized tomography urography is more accurate tan excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol 2010; 183: 48-55.
  • Wang LJ, Wong YC, Chuang CK, Huang CC, Pang ST. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol 2009; 181: 524-31.
  • Yakoubi R, Colin P, Seisen T, et al. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: A meta-analysis and a systematic review of current evidence from comparative studies. Eur J Surg Oncol 2014; 40: 1629-34.
Fuente de los datos: Dialnet